Lexeo Therapeutics (LXEO)
Develops genetic medicines for inherited cardiovascular disease and select CNS disorders.
$4.07
After hours0.00 (0.00%)
At close$4.07(−0.25%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 107.73% | 88.39M shares | |
|---|---|---|---|
| 146 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.17% | 963.8K shares | |
| 9 holders · as of Aug 19, 2026 | |||
| Strategic holders | 8.89% | 7.29M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 117.79% | ||
82.05M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 117.79%; nothing is left for Other.
13F, as of Jun 30, 2026
146 holders · 88.39M shares · 30 new positions · 90 increased · 40 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6.38M | 7.78% | +5.13M | Aug 14, 2026 |
| Affinity Asset Advisors, LLC | 5.81M | 7.08% | +757.4K | Aug 13, 2026 |
| BlackRock, Inc. | 5.74M | 7.00% | +628.6K | Aug 7, 2026 |
| Ra Capital Management, L.P. | 5.00M | 6.09% | 0 | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 4.82M | 5.88% | +400.0K | Aug 14, 2026 |
| State Street Corp | 4.35M | 5.31% | +786.5K | Aug 7, 2026 |
| Vestal Point Capital, LP | 4.32M | 5.27% | −155.0K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 4.18M | 5.09% | −2.01M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.99% | 7.29M | 13G | Dec 8, 2025 |
| Balyasny Asset Management L.P. | 9.69% | 7.18M | 13G | May 15, 2026 |
| Paradigm BioCapital Advisors LP | 8.30% | 6.18M | 13G | May 15, 2026 |
| Affinity Healthcare Fund, LP | 7.75% | 4.25M | 13G | Jun 4, 2025 |
| Suvretta Capital Management, LLC | 7.70% | 5.67M | 13G | Apr 13, 2026 |
| Vestal Point Capital, LP | 7.50% | 4.12M | 13G | Nov 14, 2025 |
| Citadel Advisors LLC | 7.20% | 5.41M | 13G | Feb 17, 2026 |
| Affinity Asset Advisors, LLC | 7.10% | 5.22M | 13G | Jan 29, 2026 |
| RA Capital Management, L.P. | 6.90% | 5.00M | 13G | Oct 27, 2025 |
| BlackRock, Inc. | 6.70% | 4.89M | 13G | Jan 21, 2026 |
| Mizuho Financial Group, Inc. | 6.60% | 2.20M | 13G | May 13, 2025 |
| State Street Corporation | 5.50% | 4.35M | 13G | Aug 7, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 5.10% | 3.70M | 13G | Feb 13, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 1,304 | $4.96 | 136,178 |
| Aug 18, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 3,345 | $4.95 | 374,472 |
| Aug 18, 2026 | Louis Edward Tamayoofficer: Chief Financial Officer | Sale | 4,117 | $4.91 | 92,907 |
| Jul 1, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 25,947 | $4.48 | 377,817 |
| Jul 1, 2026 | Narinder Pal Bhallaofficer: Chief Medical Officer | Sale | 22,306 | $4.42 | 82,194 |
| Jul 1, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 4,666 | $4.48 | 137,482 |
| Jul 1, 2026 | Louis Edward Tamayoofficer: Chief Financial Officer | Sale | 4,641 | $4.49 | 97,024 |
| May 18, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 3,342 | $5.06 | 336,764 |
| May 18, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 1,302 | $5.07 | 130,088 |
| Apr 6, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 55,000 | $5.69 | 340,106 |
House and Senate disclosures
Not reported.